Field of the Invention
The present invention is directed to biopolymer optofluidic devices, and methods for manufacturing such devices.
Description of Related Art
The field of optics is well established. Some subfields of optics include diffractive optics, micro-optics, photonics and guided wave optics. Various optical devices have been fabricated in these and other subfields of optics for research and commercial application. For example, common optical devices include lenses, diffraction gratings, photonic crystals, waveguides, optofluidic devices, etc. Optofluidics specifically refers to a class of adaptive optical circuits that integrate optical and fluidic devices together. Optofluidic devices are optical devices that incorporate one or more fluidic channels to convey fluid through the device. In this regard, optofluidic devices can be lenses, diffraction gratings, photonic crystals, waveguides, and the like. The introduction of liquids in the optical structure enables flexible fine-tuning of the optical device, and even allows reconfiguration of optical circuits such that they perform tasks optimally in a changing environment. An overview of optofluidics is available at Caltech's website: http://optofluidics.caltech.edu/optofluidics/index.html.
Optical devices and optofluidic devices are fabricated using various methods depending on the application and optical characteristics desired. However, these devices, and the fabrication methods employed in their manufacture, generally involve significant use of non-biodegradable materials. For example, glass, fused silica, and plastic are commonly used. Such materials are not biodegradable and remain in the environment for extended periods of time after the optical and optofluidic devices are removed from service and discarded. Of course, some of the materials can be recycled and reused. However, recycling also requires expenditures of natural resources and adds to the environmental costs associated with such materials.
Therefore, there exists an unfulfilled need for optofluidic devices that minimize the negative impact to the environment. In addition, there exists an unfulfilled need for optofluidic devices that provide additional functional features that are not provided by conventional optofluidic devices.
In view of the foregoing, objects of the present invention are to provide optofluidic devices that are made from a biopolymer and to provide methods for manufacturing such optofluidic devices that may be used in various applications.
One aspect of the present invention is to provide biopolymer optofluidic devices.
Another aspect of the present invention is to provide a method for manufacturing such biopolymer optofluidic devices.
One advantage of the present invention is in providing optofluidic devices that minimize the negative impact to the environment.
Another advantage of the present invention is in providing optofluidic devices that are biocompatible.
Yet another advantage of the present invention is in providing biopolymer optofluidic devices that have additional functional features that are not provided by conventional optofluidic devices.
In the above regard, inventors of the present invention recognized that biopolymers, and especially silk proteins, present novel structure and resulting functions. For example, from a materials science perspective, silks spun by spiders and silkworms represent the strongest and toughest natural fibers known and present various opportunities for functionalization, processing, and biocompatibility. Over five millennia of history accompany the journey of silk from a sought-after textile to a scientifically attractive fiber. As much as its features had captivated people in the past, silk commands considerable attention in this day and age because of its strength, elasticity, and biochemical properties. The novel material features of silks have recently been extended due to insights into self-assembly and the role of water in assembly. These insights, in turn, have led to new processing methods to generate hydrogels, ultrathin films, thick films, conformal coatings, three dimensional porous matrices, solid blocks, nanoscale diameter fibers, and large diameter fibers.
Silk-based materials achieve their impressive mechanical properties with natural physical crosslinks of thermodynamically stable protein secondary structures also known as beta sheets (β-sheets). Thus, no exogenous crosslinking reactions or post-processing crosslinking is required to stabilize the materials. The presence of diverse amino acid side chain chemistries on silk protein chains facilitates coupling chemistry to functionalize silks, such as with cytokines, morphogens, and cell binding domains. There are no known synthetic or biologically-derived polymer systems that offer this range of material properties or biological interfaces, when considering mechanical profiles, aqueous processing, ease of functionalization, diverse modes of processing, self-forming crosslinks, biocompatibility, and biodegradability.
While no other biopolymer or synthetic polymer can match the range of features outlined above for silk, some other polymers that exhibit various properties similar or analogous to silk have been identified by the inventors of the present invention. In particular, other natural biopolymers including chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers, or a combination thereof, have been identified. In view of the above noted features of biopolymers and of silk in particular, the present invention provides various novel nanopatterned biopolymer optical devices and methods for manufacturing such devices.
In accordance with one aspect of the present invention, one method of manufacturing a biopolymer optofluidic device includes providing a biopolymer, processing the biopolymer to yield a biopolymer matrix solution, providing a substrate, casting the biopolymer matrix solution on the substrate, embedding a channel mold in the biopolymer matrix solution, drying the biopolymer matrix solution to solidify a biopolymer optofluidic device, and extracting the embedded channel mold to provide a fluidic channel in the solidified biopolymer optofluidic device.
In accordance with one embodiment, the method optionally includes annealing the solidified biopolymer optofluidic device, and an additionally drying the annealed biopolymer optofluidic device in a vacuum environment or in a water vapor environment, or in both environments. In the preferred embodiment, the substrate is a template for an optical device, and the channel mold is a glass fiber. The channel mold may be embedded in the biopolymer matrix solution after the biopolymer matrix solution is cast, or suspended over the substrate, and the biopolymer matrix solution cast around the channel mold.
In one embodiment, the biopolymer may be silk and the biopolymer matrix solution is an aqueous silk fibroin solution having approximately 1.0 wt % to 30 wt % silk, inclusive, for example, 8.0 wt % silk. In other embodiments, the biopolymer may be chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers, or a combination thereof. In addition, in another embodiment, the method may also include embedding an organic material in the biopolymer optofluidic device, for instance, by adding an organic material into the biopolymer matrix solution. The added organic material may be red blood cells, horseradish peroxidase, phenolsulfonphthalein, nucleic acid, a dye, a cell, an antibody, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, proteins, peptides, small molecules, drugs, dyes, amino acids, vitamins, antixoxidants, DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, chromophores, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds, chemical dyes, antibiotics, antifungals, antivirals, light harvesting compounds such as chlorophyll, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, or a combination thereof.
Other materials may be embedded in the biopolymer or in the biopolymer matrix solution instead of, or in addition to, organic materials, depending upon the type of optofluidic device desired.
In accordance with another aspect of the present invention, an optofluidic device made of a biopolymer and having a channel therein for conveying fluid. The optofluidic device may be a lens, a microlens array, an optical grating, a pattern generator, or a beam reshaper. In one embodiment, the optofluidic device may include a nanopatterned surface thereon.
Preferably, the biopolymer is silk, chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers, or a combination thereof. In addition, in another embodiment, the biopolymer optofluidic device includes an embedded organic material. The organic material may be red blood cells, horseradish peroxidase, phenolsulfonphthalein, nucleic acid, a dye, a cell, an antibody, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, proteins, peptides, small molecules, drugs, dyes, amino acids, vitamins, antixoxidants, DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, chromophores, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds, chemical dyes, antibiotics, antifungals, antivirals, light harvesting compounds such as chlorophyll, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, or a combination thereof.
These and other advantages and features of the present invention will become more apparent from the following detailed description of the preferred embodiments of the present invention when viewed in conjunction with the accompanying drawings.
As described in detail below, optofluidic devices in accordance with the present invention have been fabricated with a cylindrical channel therein to allow conveyance of fluid therethrough using a biopolymer such as silk. As noted, biopolymer optofluidic devices generally referred to herein may incorporate various different optical devices such as lenses, diffraction gratings, photonic crystals, waveguides, and the like, that incorporate one or more fluidic channels therein to allow conveyance of fluid therethrough. In addition, the biopolymer optofluidic devices of the present invention are described herein below as being implemented with silk in view of its superior functional characteristics and processability which were noted above. In this regard, the silk utilized was silkworm silk. However, there are many different silks, including spider silk, transgenic silks, and genetically engineered silks, variants and combinations thereof and others, that may alternatively be used in accordance with the present invention to obtain a biopolymer optofluidic device.
In addition, other biodegradable polymers may be used instead of silk. For example, other biopolymers, such as chitosan, exhibit desirable mechanical properties, can be processed in water, and form generally clear films for optical applications. Other biopolymers, such as chitosan, collagen, gelatin, agarose, chitin, polyhydroxyalkanoates, pullan, starch (amylose amylopectin), cellulose, hyaluronic acid, and related biopolymers, or a combination thereof and others may alternatively be utilized in specific applications, and synthetic biodegradable polymers such as polylactic acid, polyglycolic acid, polyhydroxyalkanoates and related copolymers may also be selectively used. Some of these polymers are not as easily processed in water. Nonetheless, such polymers may be used by themselves, or in combinations with silks, and may be used in particular biopolymer optical devices.
Thus, in the example of silk, an aqueous silk fibroin solution is processed in step 14, for example, 8.0 wt % silk concentration, which is then used to manufacture the biopolymer optofluidic device. Of course, in other embodiments, the concentrations may also be varied from very dilute (approximately 1 wt %) to very high (up to 30 wt %) using either dilution or concentration, for example, via osmotic stress or drying techniques. In this regard, other embodiments may utilize different percent weight solutions to optimize flexibility or strength of the resultant biopolymer optofluidic device, depending on the application. Production of aqueous silk fibroin solution is described in detail in WIPO Publication Number WO 2005/012606 entitled “Concentrated Aqueous Silk Fibroin Solution and Uses Thereof”.
A substrate is provided in step 16 to serve as a mold in manufacturing the biopolymer optofluidic device. The aqueous biopolymer matrix solution is cast on the substrate in step 18. A channel mold for forming a fluid channel in the biopolymer optofluidic device is embedded in the cast aqueous biopolymer matrix solution in step 19 so that the aqueous biopolymer matrix solution surrounds the channel mold. In this regard, various fibers or lines can be used as the channel mold, such as lines made of nylon, polyethylene, Dacron® and Dyneema® ultra high molecular weight polyethylene (UHMWPE). In one embodiment, the channel mold may be a flexible glass fiber that is coated with a surfactant solution. In another embodiment of the present invention, the channel mold may be a flexible glass fiber without a wetting agent, depending upon the interfacial tension between the solution and the channel mold. The aqueous biopolymer matrix solution is then dried in step 20 to transition the aqueous biopolymer matrix solution to the solid phase. In this regard, the aqueous biopolymer matrix solution may be dried for a period of time such as 24 hours, and may optionally be subjected to low heat to expedite drying of the aqueous biopolymer matrix solution. Upon drying, a solidified biopolymer optofluidic device is formed on the surface of the substrate with the channel mold embedded therein.
Once the solvent of the biopolymer matrix solution has evaporated, the solidified biopolymer optofluidic device may optionally be annealed in step 22. This annealing step may be performed within a water vapor environment, such as in a chamber filled with water vapor, for different periods of time depending on the material properties desired. Typical annealing time periods may range from between two hours to two days, for example, and may also be performed in a vacuum environment. The annealed biopolymer optofluidic device is then removed from the substrate in step 24 and allowed to dry further in step 26. The embedded channel mold is subsequently extracted in step 28, such extraction being facilitated by the reduced surface tension provided by the surfactant coating of the glass fiber as discussed above.
In accordance with an alternative embodiment of the method, the cylindrical channel may be formed in the optofluidic device by first suspending the channel mold over the substrate, and then casting the aqueous biopolymer matrix solution to surround the channel mold. Correspondingly, upon drying of the aqueous biopolymer matrix solution and extraction of the channel mold, a solidified optofluidic device which has a channel therein can be readily fabricated.
The above described methods for fabricating an optofluidic device can be enhanced to provide additional features and functions. For instance, the substrate upon which the aqueous biopolymer matrix solution is cast may be a template for an optical device with surface features so that the resultant optofluidic device is provided with a patterned optical surface thereon. For instance, the substrate may be patterned for a diffraction grating, a lens, or the like, to allow use of the optofluidic device as a lens, optical grating, pattern generator, beam reshaper, and the like.
Experiments were conducted to validate the above-described method by manufacturing biopolymer optical devices and optofluidic devices. The relationship between the volume of 8 wt % silk concentration aqueous silk fibroin solution, and the resulting silk film thickness, is shown in the graph 30 of
Of course, the film properties such as thickness and biopolymer content, as well as optical features, may be altered based on the concentration of fibroin used in the process, the volume of the aqueous silk fibroin solution deposited, and the post deposition process for drying the cast solution to lock in the structure. Accurate control of these parameters is desirable to ensure the optical quality of the resultant biopolymer optofluidic device and to maintain various characteristics of the biopolymer optofluidic device, such as transparency, structural rigidity, and flexibility. Furthermore, additives to the biopolymer matrix solution may be used to alter features of the biopolymer optofluidic device such as morphology, stability, and the like, as known with polyethylene glycols, collagens, and the like.
An unpatterned biopolymer film having a thickness of 10 μm was manufactured in the above-described manner using an aqueous silk fibroin solution, and was characterized in a scanning prism coupled reflectometer from Metricon Corporation.
In addition, the unpatterned silk film 34 was also analyzed to determine transparency.
Importantly, shaped films having various thicknesses have been patterned on the nanoscale using the method of
The measured roughness of cast silk film on an optically flat surface shows measured root mean squared roughness values between 2.5 and 5 nanometers, which implies a surface roughness easily less than λ/50 at a wavelength of 633 nm. Atomic force microscope images of patterned silk diffractive optics show the levels of microfabrication obtainable by casting and lifting silk films off of appropriate molds. The images show definition in the hundreds of nanometer range and the sharpness of the corners indicates the possibility of faithful patterning down to the tens of nanometers.
With silk matrices and films demonstrated to have such structural stability and favorable optical properties as discussed above, the technological field of microfluidic devices, as well as the technological field of optofluidics can be extended so that the optofluidic devices can be manufactured as described using biopolymers such as silk and other materials. Optofluidic devices of the present invention avoid the inorganic polymer matrices required in which the network of liquids necessary are flowed and allow realization of microchannels through the biopolymer, such as silk, that define channels and reservoirs.
Of course, in other embodiments, different diameter glass fibers may be used, depending on the desired size of the channel and fluid flow characteristics therethrough. For instance, the diameter of the glass fiber may be as small as 50 microns or as large as 250 microns. In addition, different diameter glass fibers may be used in fabrication of a single optofluidic device so as to provide fluid flow channels having different flow capacities and characteristics. Further, soft lithography techniques may also be used where fluidic channels may be designed on a mask, the silk biopolymer material may be cast, the glass fibers embedded, and the silk biopolymer material detached, thereby leaving a microchannel behind.
A significant advantage of the biopolymer optofluidic devices in accordance with the present invention is the ability for the optofluidic devices to be biologically activated by embedding organic materials since they are entirely organic and biocompatible. The water-based processing that can be used, for example, for silk optofluidic devices, increases cellular survivability of embedded organic materials and likelihood of biocompatibility. Varying degrees of functionalization can be performed making both fluids and light interactive to attain a novel class of biopolymer optofluidic devices such as sensors that will increase sensitivity, detectability, and selectivity.
In other words, the optofluidic devices of the present invention can be biologically activated by embedding organic materials, such as proteins. This allows biologically induced changes to the biopolymer optofluidic device, which alters local optical characteristics of the biopolymer optofluidic device. The variation in the optical characteristics can function as an indicator of the changes occurring at the biological level. Such responsive biopolymer optofluidic devices can be implemented by the addition of proteins, peptides, nucleic acid (such as RNA and/or DNA), enzymes, protein complexes, viruses, cells, antibodies, other biomolecules, dyes or other compounds such as red blood cells, horseradish peroxidase, and phenolsulfonphthalein, other cells, tissues or other living materials, a nucleic acid, a dye, a cell, an antibody, as described further in Appendix I, enzymes, for example, peroxidase, lipase, amylose, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, DNA polymerases, glucose oxidase, laccase, cells, viruses, bacterias, proteins, peptides for molecular recognition, small molecules, drugs, dyes, amino acids, vitamins, antioxidants, plant cells, mammalian cells, and the like, DNA, RNA, RNAi, lipids, nucleotides, aptamers, carbohydrates, optically-active chromophores including beta carotene or porphyrins, light emitting organic compounds such as luciferin, carotenes and light emitting inorganic compounds, chemical dyes, antibiotics, yeast, antifungals, antivirals, and complexes such as hemoglobin, electron transport chain coenzymes and redox components, light harvesting compounds such as chlorophyll, phycobiliproteins, bacteriorhodopsin, protorhodopsin, and porphyrins and related electronically active compounds, or a combination thereof.
It should be appreciated that in other embodiments these compounds may be used to coat the surface of the optofluidic device. However, embedding such materials may be preferable since coatings can be more easily removed. As indicated above, other materials may also be embedded in the polymer or in the biopolymer matrix solution instead of, or in addition to, organic materials depending upon the type of optofluidic device desired.
As an example,
More specifically, an 8% silk fibroin solution was combined with the pH indicator phenol red to provide a 1 mg/ml concentration of the pH indicator in the aqueous biopolymer matrix solution. A volume of 1.5 ml of the phenol red/silk solution was then cast into a 7 cm2 square substrate. A surfactant solution was used to coat three 150 micron diameter optical fibers. These surfactant coated glass fibers were then placed next to each other within the bulk volume of the silk fibroin solution. The silk fibroin solution was then allowed to dry overnight to form the solidified optofluidic device, and the device was annealed in the presence of vacuum and water vapor for two hours.
The solidified optofluidic device was removed and a dilute NaOH solution with a pH=8 was flowed through one of the functionalized channels 74. The channel turned pink color upon flow of the NaOH solution. As also shown in the enlarged photograph of
Furthermore, as noted previously, additional optical functionalization of the optofluidic devices in accordance with the present invention can be attained by forming diffractive or refractive optical features on the surface of the optofluidic device 70. In particular, the aqueous biopolymer matrix solutions can be cast onto an optical element that serves as a substrate thereby forming the optical features such as nanopatterning on the surface of the optofluidic device. The substrate surfaces may be coated with Teflon™ to ensure even detachment after the aqueous biopolymer matrix solution transitions from the liquid to the solid phase. Thus, as noted, the optofluidic device may be lenses, microlens arrays, optical gratings, pattern generators, beam reshapers or other devices that have channels therein for allowing fluid to flow therethrough.
The ability to fabricate optical materials and waveguides in biopolymers, such as silk, enables a new class of optical devices to be created by bringing together the mature and diverse methodologies of optical physics and the versatility of a biological substrate. As described, the material properties of silk films are ideal for patterning on the nanoscale using casting techniques on patterned surfaces. With appropriate relief masks, silk films can be processed into versatile optical elements. The advantages of this approach combines (a) the nature of the silk films which is organic, controllably degradable, biocompatible, structurally strong; (b) the power of diffractive and transmissive optics embedded in the organic matrix; and (c) the creation of biologically active optical elements. The process explained above allows the formation of highly defined patterned structures on the nanoscale in production of bio-optical biopolymer devices.
The structural stability and ability to faithfully reproduce nanostructure makes the above described method appropriate for manufacture of many different diffractive optical structures or refractive micro and nano-optical structures using biopolymers such as silk. Among the optical elements that can be readily made are silk gratings as described above, silk micro and nano lens arrays, silk pattern generators, silk beam diffusers, and silk beam homogenizers, these optical elements having been demonstrated in silk.
The above noted attributes of the biopolymer devices in accordance with the present invention also allows manufacture of a biocompatible, low-cost, organic based solar energy systems that include solar cell elements based on biopolymers such as layered silk optics and silk films. A layered biopolymer structure such as silk matrices or other appropriate biopolymer matrices may be tailored for use as solar panels and solar cells. Such matrices may then be used in conjunction with light harvesting compounds for efficient harnessing and storage of energy in sunlight.
Antibody Stability in Silk Films
Materials—Anti-IL-8 monoclonal antibody (IgG1) was purchased from eBioscience, Inc. human polyclonal antibody IgG and human IgG ELISA Quantitation Kit were purchased from Bethyl Laboratories Inc. All other chemicals used in the study were purchased from Sigma-Aldrich (St. Louis, MO).
Antibody entrapment in silk films - human polyclonal antibody IgG—Ten ml 1mg/m1 IgG mixed with 167 ml 6% silk solution make the IgG concentration in silk film mg/g silk. 100 μl of mixed IgG solution was added to each well of 96 well plate which was placed in a fume hood with cover opened overnight. The dried film was either treated or not treated with methanol. For methanol treatment, the wells were immersed in 90% methanol solution for 5 min and dried in the fume hood. All dry 96 well plates were then stored at 4° C., room temperature, and 37° C.
Anti-IL-8 monoclonal antibody (IgG1)—0.5m1 1 mg/ml IgG1 mixed with 83 ml 6% silk solution make the IgG1 concentration in silk film 0.1 mg/g silk. 50 μl of mixed IgG1 solution was added to a well of 96 well plate which was placed in a fume hood with cover opened overnight. The dried film was either treated or not treated with methanol. For methanol treatment, the wells were immersed in 90% methanol solution for 5 min and dried in the fume hood. All dry 96 well plates were then stored at 4° C., room temperature, and 37° C.
Antibody measurement—Five wells prepared at the same condition were measured for statistic. Pure silk (without antibody) was used as a control.
For non methanol-treated samples, 100 μl of PBS buffer, pH 7.4, was added to the well which was further incubated at room temperature for 30 min to allow the film to completely dissolve. Aliquot of solution was then subjected to antibody measurement. For methanol-treated samples, 100 μl HFIP was added into each well which was further incubated at room temperature for 2 hours to allow the film completely dissolve. The silk HFIP solution was dried in a fume hood overnight. The follow step was the same as non methanol-treated samples, added PBS buffer and pipette the solution for antibody measurement.
ELISA—Polystyrene (96-well) microtitre plate was coated with 100 μL of antigen anti-Human IgG-affinity at a concentration of 10 μg/mL prepared in antigen coating buffer (bicarbonate buffer, 50 mM, pH 9.6) and then incubated overnight storage at room temperature. The wells were then washed three times with TBS-T buffer. The unoccupied sites were blocked with 1% BSA in TBS (200 μL, each well) followed by incubation for 30 minutes at room temperature. The wells were then washed three times with TBS-T. The test and control wells were then diluted with 100 μL. of serially diluted serum. Each dilution was in TBS buffer. Serially diluted blanks corresponding to each dilution were also present. The plate was then incubated for 1 h at room temperature. The plate was washed again with TBS-T buffer (five times). Bound antibodies were assayed with an appropriate conjugate of anti-human IgG-HRP (1:100,000), 100 μL of it was coated in each well and kept at room temperature for 1 hour. Washing of the plate with TBS-T (five times) was followed by addition of 100 μl , TMB in each well and incubation at room temperature for 5-20 min. The absorbance of each well was monitored at 450 nm on a VersaMax microplate reader (Molecular devices, Sunnyvale, CA).
While various embodiments in accordance with the present invention have been shown and described, it is understood that the invention is not limited thereto. The present invention may be changed, modified and further applied by those skilled in the art. Therefore, this invention is not limited to the detail shown and described previously, but also includes all such changes and modifications.
The foregoing description of the aspects and embodiments of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise form disclosed. Those of skill in the art will recognize certain modifications, permutations, additions, and combinations of those embodiments are possible in light of the above teachings or may be acquired from practice of the invention. Therefore, the present invention also covers various modifications and equivalent arrangements that fall within the purview of the appended claims.
This application is a Continuation of U.S. patent application Ser. No. 12/513,423 filed on May 4, 2009, entitled “Biopolymer Optofluidic Device and Method of Manufacturing the Same” (incorporated herein by reference in its entirety), which is a National Stage Entry of International Patent Application No. PCT/US2007/083634 filed Nov. 5, 2007 (incorporated herein by reference in its entirety), and claims the benefit of priority of U.S. Provisional Application Ser. No. 60/856,297 filed on Nov. 3, 2006, entitled “Biopolymer Devices and Methods for Manufacturing the Same” (incorporated herein by reference in its entirety).
The invention was made with government support under grant numbers EB002520 awarded by the National Institutes of Health, DMR0402849 awarded by the National Science Foundation, and FA9550-04-1-0363 awarded by the United States Air Force. The government has certain rights in this invention.
Number | Name | Date | Kind |
---|---|---|---|
4676640 | Briggs | Jun 1987 | A |
4977902 | Sekino et al. | Dec 1990 | A |
4999295 | Asakura et al. | Mar 1991 | A |
5244799 | Anderson | Sep 1993 | A |
5252285 | Lock | Oct 1993 | A |
5427096 | Bogusiewicz et al. | Jun 1995 | A |
5474915 | Dordick et al. | Dec 1995 | A |
5512218 | Gresser et al. | Apr 1996 | A |
5552270 | Khrapko et al. | Sep 1996 | A |
6134045 | Jiang et al. | Oct 2000 | A |
6150491 | Akkara | Nov 2000 | A |
6284418 | Trantolo | Sep 2001 | B1 |
6489446 | Rothstein et al. | Dec 2002 | B1 |
6753064 | Nakama et al. | Jun 2004 | B1 |
6753131 | Rogers et al. | Jun 2004 | B1 |
6924503 | Cheng et al. | Aug 2005 | B2 |
6989897 | Chan et al. | Jan 2006 | B2 |
6992325 | Huang | Jan 2006 | B2 |
7162127 | Ohtsu | Jan 2007 | B2 |
7223609 | Anvar et al. | May 2007 | B2 |
7267958 | Dordick et al. | Sep 2007 | B2 |
7427371 | Kawanishi | Sep 2008 | B2 |
7476398 | Doillon et al. | Jan 2009 | B1 |
7498802 | Takahata | Mar 2009 | B2 |
7674882 | Kaplan et al. | Mar 2010 | B2 |
7713778 | Li et al. | May 2010 | B2 |
7828997 | Otoshi | Nov 2010 | B2 |
8005526 | Martin et al. | Aug 2011 | B2 |
8348974 | Asakura | Jan 2013 | B2 |
8529835 | Kaplan | Sep 2013 | B2 |
8563329 | Yin | Oct 2013 | B2 |
8663909 | Gazenko | Mar 2014 | B2 |
8666471 | Rogers | Mar 2014 | B2 |
8715740 | Wang | May 2014 | B2 |
8722067 | Wang | May 2014 | B2 |
8747886 | Amsden | Jun 2014 | B2 |
9171794 | Rafferty | Oct 2015 | B2 |
9513405 | Kaplan et al. | Dec 2016 | B2 |
9802374 | Kaplan et al. | Oct 2017 | B2 |
20010002417 | Akkara et al. | May 2001 | A1 |
20010003043 | Metspalu et al. | Jun 2001 | A1 |
20030020915 | Schueller et al. | Jan 2003 | A1 |
20030162696 | Mihara | Aug 2003 | A1 |
20030203366 | Lim | Oct 2003 | A1 |
20030214057 | Huang | Nov 2003 | A1 |
20040001299 | van Haaster et al. | Jan 2004 | A1 |
20040029241 | Hahn et al. | Feb 2004 | A1 |
20040081384 | Datesman et al. | Apr 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20040266992 | Migliaresi et al. | Dec 2004 | A1 |
20050008675 | Bhatia et al. | Jan 2005 | A1 |
20050151966 | Packirisamy et al. | Jul 2005 | A1 |
20050164920 | Doherty et al. | Jul 2005 | A1 |
20050169962 | Bhatia et al. | Aug 2005 | A1 |
20050194365 | Li | Sep 2005 | A1 |
20050208469 | Daunert et al. | Sep 2005 | A1 |
20050213868 | Cunningham | Sep 2005 | A1 |
20050217990 | Sibbett et al. | Oct 2005 | A1 |
20050276791 | Hansford et al. | Dec 2005 | A1 |
20060024813 | Warthoe | Feb 2006 | A1 |
20060042822 | Azeyanagi et al. | Mar 2006 | A1 |
20060091571 | Akutsu et al. | May 2006 | A1 |
20060111517 | Feucht et al. | May 2006 | A1 |
20060134606 | Montagu | Jun 2006 | A1 |
20060141617 | Desai et al. | Jun 2006 | A1 |
20060159837 | Kaplan et al. | Jul 2006 | A1 |
20060177479 | Giachelli et al. | Aug 2006 | A1 |
20060178655 | Santini et al. | Aug 2006 | A1 |
20060205927 | Jin et al. | Sep 2006 | A1 |
20060226575 | Maghribi et al. | Oct 2006 | A1 |
20060236436 | Li et al. | Oct 2006 | A1 |
20070007661 | Burgess et al. | Jan 2007 | A1 |
20070009968 | Cunningham et al. | Jan 2007 | A1 |
20070026064 | Yoder et al. | Feb 2007 | A1 |
20070031607 | Dubson et al. | Feb 2007 | A1 |
20070042505 | Israel et al. | Feb 2007 | A1 |
20070058254 | Kim | Mar 2007 | A1 |
20070073130 | Finch et al. | Mar 2007 | A1 |
20070113355 | Knight | May 2007 | A1 |
20070178240 | Yamazaki et al. | Aug 2007 | A1 |
20070187862 | Kaplan et al. | Aug 2007 | A1 |
20070214520 | Scheibel et al. | Sep 2007 | A1 |
20070224677 | Neumann | Sep 2007 | A1 |
20070233208 | Kurtz et al. | Oct 2007 | A1 |
20070275030 | Muratoglu et al. | Nov 2007 | A1 |
20080019925 | Begleiter | Jan 2008 | A1 |
20080038236 | Gimble et al. | Feb 2008 | A1 |
20080085272 | Kaplan et al. | Apr 2008 | A1 |
20080152281 | Lundquist et al. | Jun 2008 | A1 |
20080203431 | Garcia et al. | Aug 2008 | A1 |
20080239755 | Parker et al. | Oct 2008 | A1 |
20080288037 | Neysmith et al. | Nov 2008 | A1 |
20090028910 | DeSimone et al. | Jan 2009 | A1 |
20090171467 | Mann et al. | Jul 2009 | A1 |
20090202614 | Kaplan et al. | Aug 2009 | A1 |
20090208555 | Kuttler et al. | Aug 2009 | A1 |
20090263430 | Scheibel et al. | Oct 2009 | A1 |
20100028451 | Kaplan et al. | Feb 2010 | A1 |
20100046902 | Kaplan et al. | Feb 2010 | A1 |
20100063404 | Kaplan et al. | Mar 2010 | A1 |
20100068740 | Kaplan et al. | Mar 2010 | A1 |
20100070068 | Kaplan et al. | Mar 2010 | A1 |
20100100975 | Sutherland et al. | Apr 2010 | A1 |
20100120116 | Kaplan et al. | May 2010 | A1 |
20110135697 | Omenetto et al. | Jun 2011 | A1 |
20120034291 | Amsden et al. | Feb 2012 | A1 |
20130243693 | Omenetto | Sep 2013 | A1 |
20130323811 | Kaplan et al. | Dec 2013 | A1 |
20140205797 | Kaplan et al. | Jul 2014 | A1 |
20160376331 | Kaplan et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
0245509 | Nov 1987 | EP |
1025988 | Aug 2000 | EP |
1116987 | Jul 2001 | EP |
1166987 | Jan 2002 | EP |
1209280 | May 2002 | EP |
1467224 | Oct 2004 | EP |
60-142259 | Jul 1985 | JP |
60-155129 | Aug 1985 | JP |
H01-135853 | May 1989 | JP |
01280242 | Nov 1989 | JP |
H02-86799 | Mar 1990 | JP |
11042106 | Feb 1999 | JP |
H11-123791 | May 1999 | JP |
H11-183854 | Jul 1999 | JP |
2000-019119 | Jan 2000 | JP |
2000-096490 | Apr 2000 | JP |
2000-143472 | May 2000 | JP |
2000-180969 | Jun 2000 | JP |
2001-147301 | May 2001 | JP |
2001280242 | Oct 2001 | JP |
2002-287377 | Oct 2002 | JP |
2003-195001 | Jul 2003 | JP |
2003-322729 | Nov 2003 | JP |
2004162209 | Jun 2004 | JP |
2004-307661 | Nov 2004 | JP |
2005031724 | Feb 2005 | JP |
2005-530983 | Oct 2005 | JP |
2006-119424 | May 2006 | JP |
2006241450 | Sep 2006 | JP |
2011-123791 | Jun 2011 | JP |
05-039368 | Oct 2012 | JP |
20060027113 | Mar 2006 | KR |
20070060822 | Jun 2007 | KR |
20080069553 | Jul 2008 | KR |
WO-1993015244 | Aug 1993 | WO |
WO-9605510 | Feb 1996 | WO |
WO-200031752 | Jun 2000 | WO |
WO-0110464 | Feb 2001 | WO |
WO-200185637 | Nov 2001 | WO |
WO-03038033 | May 2003 | WO |
WO-04000915 | Dec 2003 | WO |
WO-2004071949 | Aug 2004 | WO |
WO-2004092250 | Oct 2004 | WO |
WO-05012606 | Feb 2005 | WO |
WO-2005019503 | Mar 2005 | WO |
WO-05031724 | Apr 2005 | WO |
WO-2005103670 | Nov 2005 | WO |
WO-05123114 | Dec 2005 | WO |
WO-2006020507 | Feb 2006 | WO |
WO-2008004356 | Jan 2008 | WO |
WO-2008118211 | Oct 2008 | WO |
WO-2008127402 | Oct 2008 | WO |
WO-2008127403 | Oct 2008 | WO |
WO-2008127404 | Oct 2008 | WO |
WO-2008127405 | Oct 2008 | WO |
WO-2008140562 | Nov 2008 | WO |
WO-2009061823 | May 2009 | WO |
WO-2010042798 | Apr 2010 | WO |
WO-2010059963 | May 2010 | WO |
WO-2010126640 | Nov 2010 | WO |
Entry |
---|
Anderson, J. et al., Bioactive Silk-Like Protein Polymer Films on Silicon Devices, Materials Research Society Synthesis and Thermoelectric Properties, 330:171-177 (1994). |
Bai, J. et al., Regenerated spider silk as a new biomaterial for MEMS, Biomed Microdevices, 8:317-323 (2006). |
Chrisey, D.B. et al., Laser Deposition of Polymer and Biomaterial Films, Chem. Rev 103(2):553-576 (2003). |
Extended European Search Report for EP 09767706.6, 6 pages (dated Jan. 8, 2013). |
Extended European Search Report for EP 13156510.3, 7 pages (dated Oct. 11, 2013). |
Extended European Search Report for EP 13156523.6, 9 pages (dated Dec. 18, 2013). |
Fukuoka T. et al., Enzymatic Polymerization of Tyrosine Derivatives. Peroxidase- and Protease-Catalyzed Synthesis of Poly(tyrosine)s with Different Structures, Biomacromolecules 3(4):768-774 (2002). |
International Search Report for PCT/US2007/083600, 3 pages (dated Nov. 5, 2008). |
International Search Report for PCT/US2007/083620, 3 pages (dated Dec. 5, 2008). |
International Search Report for PCT/US2007/083634, 3 pages (dated Nov. 5, 2008). |
International Search Report for PCT/US2007/083642, 3 pages (dated Nov. 5, 2008). |
International Search Report for PCT/US2007/083646, 4 pages (dated Dec. 15, 2008). |
International Search Report for PCT/US2011/032195, 3 pages (dated Oct. 27, 2011). |
International Search Report of PCT/US2007/083605, dated Dec. 15, 2008, 6 pages. |
International Search Report of PCT/US2007/083639, dated Dec. 12, 2008, 5 pages. |
International Search Report of PCT/US2008/082487, dated Feb. 27, 2009, 3 pages. |
International Search Report of PCT/US2009/047751, dated Feb. 2, 2010, 3 pages. |
International Search Report of PCT/US2010/022701, dated Mar. 31, 2010, 2 pages. |
International Search Report of PCT/US2010/024004, dated Nov. 26, 2010, 5 pages. |
International Search Report of PCT/US2010/042585, dated May 25, 2011, 8 pages. |
International Search Report of PCT/US2010/047307, dated Apr. 28, 2011, 3 pages. |
International Search Report of PCT/US2010/050468, dated Jan. 6, 2011, 3 pages. |
International Search Report of PCT/US2011/028094, dated Jul. 14, 2011, 4 pages. |
International Search Report of PCT/US2011/041002, 4 pages (dated Feb. 29, 2012). |
IPRP for PCT/US2007/083642, 6 pages (dated May 5, 2009). |
IPRP of PCT/US2007/083600, dated May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083605, dated May 5, 2009, 10 pages. |
IPRP of PCT/US2007/083620, dated May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083634, dated May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083639, dated May 5, 2009, 6 pages. |
IPRP of PCT/US2007/083646, dated May 5, 2009, 10 pages. |
IPRP of PCT/US2008/082487, dated May 11, 2010, 10 pages. |
IPRP of PCT/US2009/047751, dated Dec. 18, 2010, 5 pages. |
IPRP of PCT/US2010/022701, dated Aug. 2, 2011, 5 pages. |
IPRP of PCT/US2010/024004, dated Aug. 16, 2011, 6 pages. |
IPRP of PCT/US2010/042585, dated Jan. 24, 2012, 6 pages. |
IPRP of PCT/US2010/047307, dated Mar. 6, 2012, 5 pages. |
Jiang, W. et al, Silicon and Polymer Nanophotonic Devices Based on Photonic Crystals, Proceedings of the International Society of Optical Engineering, 6124(1):612410-1(2006). |
Jin, H.J. et al., Water-Stable Silk Films with Reduced β-Sheet Content, Advanced Functional Materials, 15:1241-1247 (2005). |
Joglekar, A.P. et al., A study of the deterministic character of optical damage by femtosecond laser pulses and applications to nanomachining, Appl. Phys. B., 77: 25-30 (2003). |
Kouba et al., Fabrication of Nanoimprint Stamps for Photonic Crystals, Journal of Physics: Conference Series, 34(1):897-903 (2006). |
Lawrence, B.D. et al., Bioactive silk protein biomaterial systems for optical devices, Biomacromolecules, 9:1214-1220 (2008). |
Liu, Y. et al., 3D femtosecond laser patterning of collagen for directed cell attachment, Biomaterials, 26(22):4597-605 (2005). |
Min, B.M. et al., Regenerated Silk Fibroin Nanofibers: Water Vapor-Induced Structural Changes and Their Effects on the Behavior of Normal Human Cells, Macromol. Biosci., 6(4):285-292 (2006). |
Minoura, N. et al., Attachment and Growth of Cultured Fibroblast Cells on Silk Protein Matrices, J. Biomed. Mater. Res. 29(10):1215-1221 (1995). |
Notification of Transmittal of International Search Report and the Written Opinion of PCT/US2011/032195, dated Oct. 27, 2011, 2 pages. |
Partial European Search Report for EP 13156523.6, 6 pages (dated Aug. 28, 2013). |
Ramanujam, P.S., Optical Fabrication of Nano-Structured Biopolymer Surfaces, Opt. Mater. 27:1175-1177 (2005). |
Tamada, Y., New Process to Form a Silk Fibroin Porous 3-D Structure, Biomacromolecules, 6:3100-3106 (2005). |
Tu, D. et al., A ZEP520-LOR Bilayer Resist Lift-Off Process by E-Beam Lithography for Nanometer Pattern Transfer, Proceedings of the 7th IEEE Conference on Nanotechnology, 624-627 (2007). |
Verma, M.K. et al., Embedded Template-Assisted Fabrication of Complex Microchannels in PDMS and Design of a Microfluidic Adhesive, Langmuir, 22(24)10291-10295 (2006). |
Wang, L. et al., Fabrication of Polymer Photonic Crystal Superprism Structures Using Polydimethylsiloxane Soft Molds Journal of Applied Physics, 101(11):114316/1-6 (2007). |
Wang, X. et al., Biomaterial coatings by stepwise deposition of silk fibroin, Langmuir, 21(24):11335-41 (2005). |
Written Opinion for PCT/US2011/032195, 5 pages (dated Oct. 27, 2011). |
Written Opinion for PCT/US2007/083600, 5 pages (dated Nov. 5, 2008). |
Written Opinion for PCT/US2007/083620, 5 pages (dated Dec. 5, 2008). |
Written Opinion for PCT/US2007/083634, dated Nov. 5, 2008 (5 pages). |
Written Opinion for PCT/US2007/083642, 5 pages (dated Nov. 5, 2008). |
Written Opinion for PCT/US2007/083646, 9 pages (dated Dec. 15, 2008). |
Written Opinion of PCT/US2007/083605, dated Dec. 15, 2008, 9 pages. |
Written Opinion of PCT/US2008/082487, dated Feb. 27, 2009, 9 pages. |
Written Opinion of PCT/US2009/047751, dated Feb. 2, 2010, 4 pages. |
Written Opinion of PCT/US2010/022701, dated Mar. 31, 2010, 4 pages. |
Written Opinion of PCT/US2010/024004, dated Nov. 26, 2010, 5 pages. |
Written Opinion of PCT/US2010/042585, dated May 25, 2011, 5 pages. |
Written Opinion of PCT/US2010/047307, dated Apr. 28, 2011, 4 pages. |
Xu, P. and Kaplan, D.L., Horseradish peroxidase catalyzed polymerization of tyrosine derivatives for nanoscale surface patterning, Journal of Macromolecular Science, Part A: Pure and Applied Chemistry, 41(12):1437-1445 (2004). |
Yang, L.J. et al., Fabrication of SU-8 embedded microchannels with circular cross-section, International Journal of Machine Tools & Manufacturing, 44:1109-1114 (2004). |
Whitesides, G. M. et al, Soft Lithography in Biology and Biochemistry, Annu. Rev. Biomed. Eng., 3:335-73 (2001). |
Number | Date | Country | |
---|---|---|---|
20140349380 A1 | Nov 2014 | US |
Number | Date | Country | |
---|---|---|---|
60856297 | Nov 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12513423 | US | |
Child | 14154134 | US |